Aptus Pharma
345.05
-345.05(-100.00%)
Market Cap₹236.70 Cr
PE Ratio-
Company Performance:
1D-100.00%
1M-100.00%
6M-100.00%
1Y-100.00%
5Y-100.00%
View Company Insightsright
More news about Aptus Pharma
09Jan 26
Apple faces $38 billion fine risk as CCI defends global turnover-based penalty law in antitrust case
The Competition Commission of India defends its global turnover-based penalty law against Apple's legal challenge, arguing it provides necessary deterrence for multinational companies. Apple faces potential fines up to $38 billion following a CCI investigation into alleged app store dominance misuse. The case involves disputes over retrospective application and information disclosure requirements, with broader implications for antitrust enforcement against global technology companies in India.
 no imag found
08Jan 26
Apple iPhone 17e Launch Timeline Confirmed: February 2026 Release Expected
Apple is preparing to launch the iPhone 17e in February 2026, featuring a 6.1-inch 120Hz OLED display, A19 chip, 8GB RAM, 48MP camera, and budget-friendly pricing starting around Rs 64,000 in India. The device represents Apple's strategy to capture the budget-conscious market segment while maintaining premium features and ecosystem integration.
 no imag found
07Jan 26
Apple iPhones to Get 200MP Camera by 2028, Says Morgan Stanley Report
Morgan Stanley forecasts Apple will introduce Samsung-supplied 200MP cameras in iPhone 21 Pro models by 2028, extending beyond earlier iPhone 18 predictions. The timeline allows supply chain diversification beyond Sony and potential U.S. production at Samsung's Austin facility. Apple is also exploring STMicroelectronics for LiDAR supply, with under-display Face ID expected in 2027 for the iPhone's 20th anniversary.
 no imag found
31Dec 25
Apple's Restrained AI Strategy Set To Pay Dividends In 2026: Report
Apple's measured AI investment strategy contrasts sharply with aggressive competitor spending, allowing the company to maintain over $130 billion in cash reserves. The tech giant plans a major Siri overhaul for spring 2026, featuring enhanced conversational abilities powered by Google's Gemini technology. Recent executive changes, including Mike Rockwell taking over Siri development, signal Apple's renewed focus on AI capabilities.
 no imag found
12Dec 25
Aptus Pharma Expands OTC Business in Gujarat Market
Aptus Pharma Limited is expanding its over-the-counter (OTC) business in Gujarat through its AptusWellCare Division. The expansion focuses on face care, body care, and hair care products, leveraging brands like Timglo, Kerava, and Shirovita. The company plans to enhance its product portfolio, including upcoming launches in hygiene care, pain relief, and oral care. To support this growth, Aptus Pharma is strengthening its field force and expanding its distributor network across Gujarat.
 no imag found
11Dec 25
Trump Says Apple CEO Discussed Hiring Difficulties in Recent Conversation
Trump disclosed that Apple's CEO shared concerns about hiring difficulties during a recent conversation. The discussion highlighted ongoing recruitment challenges facing the technology sector. This revelation provides insight into current workforce acquisition difficulties experienced by major technology corporations.
 no imag found
21Nov 25
Aptus Pharma Limited Expands into Urology Therapy Segment
Aptus Pharma Limited announces strategic expansion into the urology therapy segment. The company plans to launch multiple products, including Solifenacin Succinate Tablets for overactive bladder and Tamsulosin Hydrochloride Capsules for benign prostatic hyperplasia, subject to regulatory approvals. This move targets the growing global urology devices market, projected to reach $62.76 billion by 2028. The company aims to leverage its existing distribution network and manufacturing capabilities, while exploring partnerships to support growth in this new segment.
 no imag found
11Nov 25
Aptus Pharma Limited Reports Robust 47% Revenue Growth in H1
Aptus Pharma Limited announced robust financial results for H1 FY24. Total revenue increased by 47.38% to Rs. 1,437.75 lakhs, EBITDA grew by 36.12% to Rs. 294.55 lakhs, and PAT rose by 33.81% to Rs. 174.69 lakhs compared to the previous year. The company experienced slight margin compression with EBITDA margin at 20.49% and PAT margin at 12.15%. Growth was attributed to product portfolio expansion, strengthened marketing network, and improved operational efficiency. The company plans to continue investing in new products, digital initiatives, and distribution expansion.
 no imag found
Aptus Pharma
345.05
-345.05
(-100.00%)
1 Year Returns:-100.00%
Industry Peers
LG Electronics
1,318.80
(-4.90%)
Voltas
1,235.40
(-1.14%)
Blue Star
1,528.30
(-1.80%)
Amber Enterprises
6,281.50
(-4.53%)
Crompton Greaves
231.91
(-0.29%)
V-Guard Industries
322.70
(+2.22%)
Whirlpool
814.40
(-1.91%)
Eureka Forbes
463.35
(+0.84%)
TTK Prestige
443.55
(-0.37%)
Symphony
728.30
(+0.59%)